Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Transthyretin Market by Type (AG-10, ALN-TTRsc02, CRX-1008, EDE-1307, Inotersen Sodium, Others), By Application (Familial Amyloid Neuropathies, Alzheimer’s Disease, Cardomyopathy, Neuropathy, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Transthyretin Market by Type (AG-10, ALN-TTRsc02, CRX-1008, EDE-1307, Inotersen Sodium, Others), By Application (Familial Amyloid Neuropathies, Alzheimer’s Disease, Cardomyopathy, Neuropathy, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 317334 4200 Pharma & Healthcare 377 203 Pages 4.5 (37)
                                          

Market Overview:


The global transthyretin market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of transthyretin-related diseases, rising awareness about these diseases, and the launch of novel therapeutics. Based on type, the global transthyretin market is segmented into AG-10, ALN-TTRsc02, CRX-1008, EDE-1307, inotersen sodium (IONIS), and others. IONIS is expected to dominate the market during the forecast period owing to its high efficacy and safety profile. Based on application, familial amyloid neuropathies (FANs) are estimated to account for a major share of the global transthyretin market in 2018. This can be attributed to increasing awareness about FANs and availability of novel therapies for their treatment such as IONIS and EDE 1307. Alzheimer's disease (AD) is another key application area for transthyretin therapeutics due to rising incidence rates globally. Other key applications areas include cardiomyopathy and neuropathy. Geographically, North America dominates the global transthyretin market followed by Europe owingto early adoption of novel therapies in these regions coupled with strong presenceof leading players such as Ionis Pharmaceuticals Inc.


Global Transthyretin Industry Outlook


Product Definition:


A serum protein that transports thyroid hormones and retinol (vitamin A) in the blood. It is important for normal fetal development and metabolism.


AG-10:


AG-10 is a form of transthyretin, which is an amino acid that the body cannot produce and must be obtained from external sources. It functions as a blood clotting agent and helps in maintaining the fluid levels in eyes. The main function of AG-10 is to help maintain normal retinal functioning by helping with blood vessel dilation & constriction, thus enabling normal vision.


ALN-TTRsc02:


ALN-TTRsc02 is a genetically engineered form of transthyretin, which is produced by the modification of human tTR-type 1 cell line. ALN-TTRsc02 has an amino acid sequence similar to that of native transthyretin and can bind all four types of thyroid hormones with high affinity.


Application Insights:


Familial amyloid neuropathy (FAN) was the leading application segment in 2017 and accounted for a revenue share of over 40%. The increasing prevalence of FAN is one of the major factors driving this segment. According to data published by Genetics Home Reference, around 1 in 4,000 babies are born with FAN.


The others segment includes transthyretin-related disorders such as cardiomyopathy and nephrological disease. Cardiomyopathy is a common disorder associated with TTR; however, it can be managed through lifestyle modifications along with medication if needed. Thus, this application segment is expected to witness lucrative growth during the forecast period owing to rising awareness about treatment options for cardiomyopathy among patients across the globe.


Regional Analysis:


North America dominated the global market in 2017. The presence of a large number of players coupled with high R&D expenditure and focus on product innovation is expected to drive the regional market over the forecast period. In addition, increasing prevalence of neurodegenerative diseases, rising geriatric population and availability of reimbursement are some other factors that can be attributed to regional growth.


Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to untapped opportunities in this region. There has been an increase in awareness regarding transthyretin deficiency among patients as well as physicians due to which there has been an upsurge in demand for AG-10, ALN-TTRsc02 and CRX-1008 products from countries such as China & Japan & South Korea etc., thereby driving growth across this region.


Growth Factors:


  • Increasing prevalence of transthyretin-related diseases such as amyloidosis, familial amyloid polyneuropathy, and senile systemic amyloidosis
  • Growing demand for novel therapeutics for the treatment of transthyretin-related diseases
  • Rising awareness about transthyretin-related diseases among patients and healthcare professionals
  • increasing investment in research and development activities for the discovery of new therapies for transthyretin-related diseases
  • growing number of clinical trials evaluating novel therapeutics for the treatment of transthyretin-related diseases

Scope Of The Report

Report Attributes

Report Details

Report Title

Transthyretin Market Research Report

By Type

AG-10, ALN-TTRsc02, CRX-1008, EDE-1307, Inotersen Sodium, Others

By Application

Familial Amyloid Neuropathies, Alzheimer's Disease, Cardomyopathy, Neuropathy, Others

By Companies

Alnylam Pharmaceuticals Inc, Arcturus Therapeutics Inc, Ionis Pharmaceuticals Inc, Neurimmune Holding AG, Pfizer Inc, Prothena Corp Plc, Regeneron Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

203

Number of Tables & Figures

143

Customization Available

Yes, the report can be customized as per your need.


Global Transthyretin Market Report Segments:

The global Transthyretin market is segmented on the basis of:

Types

AG-10, ALN-TTRsc02, CRX-1008, EDE-1307, Inotersen Sodium, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Familial Amyloid Neuropathies, Alzheimer's Disease, Cardomyopathy, Neuropathy, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Alnylam Pharmaceuticals Inc
  2. Arcturus Therapeutics Inc
  3. Ionis Pharmaceuticals Inc
  4. Neurimmune Holding AG
  5. Pfizer Inc
  6. Prothena Corp Plc
  7. Regeneron Pharmaceuticals Inc
  8. Alnylam Pharmaceuticals Inc

Global Transthyretin Market Overview


Highlights of The Transthyretin Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. AG-10
    2. ALN-TTRsc02
    3. CRX-1008
    4. EDE-1307
    5. Inotersen Sodium
    6. Others
  1. By Application:

    1. Familial Amyloid Neuropathies
    2. Alzheimer's Disease
    3. Cardomyopathy
    4. Neuropathy
    5. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Transthyretin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Transthyretin Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Transthyretin is a protein that helps control the flow of blood. It is found in the blood vessels and in the central nervous system. Transthyretin helps to keep your heart functioning properly and can help to prevent strokes.

Some of the major players in the transthyretin market are Alnylam Pharmaceuticals Inc, Arcturus Therapeutics Inc, Ionis Pharmaceuticals Inc, Neurimmune Holding AG, Pfizer Inc, Prothena Corp Plc, Regeneron Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Transthyretin Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Transthyretin Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Transthyretin Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Transthyretin Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Transthyretin Market Size & Forecast, 2020-2028       4.5.1 Transthyretin Market Size and Y-o-Y Growth       4.5.2 Transthyretin Market Absolute $ Opportunity

Chapter 5 Global  Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2  Market Size Forecast by Type
      5.2.1 AG-10
      5.2.2 ALN-TTRsc02
      5.2.3 CRX-1008
      5.2.4 EDE-1307
      5.2.5 Inotersen Sodium
      5.2.6 Others
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global  Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2  Market Size Forecast by Applications
      6.2.1 Familial Amyloid Neuropathies
      6.2.2 Alzheimer's Disease
      6.2.3 Cardomyopathy
      6.2.4 Neuropathy
      6.2.5 Others
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Transthyretin Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Transthyretin Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America  Analysis and Forecast
   9.1 Introduction
   9.2 North America  Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America  Market Size Forecast by Type
      9.6.1 AG-10
      9.6.2 ALN-TTRsc02
      9.6.3 CRX-1008
      9.6.4 EDE-1307
      9.6.5 Inotersen Sodium
      9.6.6 Others
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America  Market Size Forecast by Applications
      9.10.1 Familial Amyloid Neuropathies
      9.10.2 Alzheimer's Disease
      9.10.3 Cardomyopathy
      9.10.4 Neuropathy
      9.10.5 Others
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe  Analysis and Forecast
   10.1 Introduction
   10.2 Europe  Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe  Market Size Forecast by Type
      10.6.1 AG-10
      10.6.2 ALN-TTRsc02
      10.6.3 CRX-1008
      10.6.4 EDE-1307
      10.6.5 Inotersen Sodium
      10.6.6 Others
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe  Market Size Forecast by Applications
      10.10.1 Familial Amyloid Neuropathies
      10.10.2 Alzheimer's Disease
      10.10.3 Cardomyopathy
      10.10.4 Neuropathy
      10.10.5 Others
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific  Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific  Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific  Market Size Forecast by Type
      11.6.1 AG-10
      11.6.2 ALN-TTRsc02
      11.6.3 CRX-1008
      11.6.4 EDE-1307
      11.6.5 Inotersen Sodium
      11.6.6 Others
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific  Market Size Forecast by Applications
      11.10.1 Familial Amyloid Neuropathies
      11.10.2 Alzheimer's Disease
      11.10.3 Cardomyopathy
      11.10.4 Neuropathy
      11.10.5 Others
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America  Analysis and Forecast
   12.1 Introduction
   12.2 Latin America  Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America  Market Size Forecast by Type
      12.6.1 AG-10
      12.6.2 ALN-TTRsc02
      12.6.3 CRX-1008
      12.6.4 EDE-1307
      12.6.5 Inotersen Sodium
      12.6.6 Others
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America  Market Size Forecast by Applications
      12.10.1 Familial Amyloid Neuropathies
      12.10.2 Alzheimer's Disease
      12.10.3 Cardomyopathy
      12.10.4 Neuropathy
      12.10.5 Others
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA)  Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA)  Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA)  Market Size Forecast by Type
      13.6.1 AG-10
      13.6.2 ALN-TTRsc02
      13.6.3 CRX-1008
      13.6.4 EDE-1307
      13.6.5 Inotersen Sodium
      13.6.6 Others
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA)  Market Size Forecast by Applications
      13.10.1 Familial Amyloid Neuropathies
      13.10.2 Alzheimer's Disease
      13.10.3 Cardomyopathy
      13.10.4 Neuropathy
      13.10.5 Others
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Transthyretin Market: Competitive Dashboard
   14.2 Global Transthyretin Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Alnylam Pharmaceuticals Inc
      14.3.2 Arcturus Therapeutics Inc
      14.3.3 Ionis Pharmaceuticals Inc
      14.3.4 Neurimmune Holding AG
      14.3.5 Pfizer Inc
      14.3.6 Prothena Corp Plc
      14.3.7 Regeneron Pharmaceuticals Inc
      14.3.8 Alnylam Pharmaceuticals Inc

Our Trusted Clients

Contact Us